

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Eplerenone is a potassium-sparing diuretic that selectively blocks aldosterone activation of the mineralcorticoid receptor (IC50 = 122 nM), demonstrating little activity towards other steroid receptors (IC50 > 9 µM for glucocorticoid, androgen, progesterone, and estrogen receptors), and is indicated for the treatment of hypertension and heart failure. |
| Administration | Dosage | Frequency | Description | References | ||
| Sprague-Dawley rats | SU-5416/hypoxia-induced PAH model | Chow supplementation | 0.6 mg/1g chow | Starting immediately after SU-5416 administration and continued for 21 days | To assess the effect of Eplerenone on PAH, results showed that Eplerenone significantly attenuated pulmonary hypertension and pulmonary vascular fibrosis. | Circulation. 2014 Jul 8;130(2):168-79 |
| Mice | Obese diabetic db/db mice | Chow | 100 mg/kg/day | Once daily for 16 weeks | To evaluate the effect of Eplerenone on the expression of inflammatory factors, adiponectin, and PPARγ in adipose tissue and heart of obese diabetic mice. Results showed that Eplerenone reduced the expression of TNF-α, MCP-1, PAI-1, and CD68 in adipose tissue, and increased the expression of adiponectin and PPARγ in adipose tissue and heart. | Circulation. 2008 Apr 29;117(17):2253-61. |
| Mice | Aldosterone infusion model | Oral gavage | 100 mg/kg/d | Once daily for 14 days | Eplerenone rescued aldosterone-induced EPC dysfunction, impaired vascularization, and endothelial dysfunction via MR blockade, independent of blood pressure effects. | Eur Heart J. 2011 May;32(10):1275-86. |
| C57BL/6 mice | High-fat diet-induced obesity model | Oral | 200 mg/kg/day | Once daily for 14 weeks | To evaluate the effect of eplerenone on obesity-induced endothelial dysfunction. Results showed that eplerenone treatment prevented the impairment of endothelium-dependent relaxation caused by obesity. | Eur Heart J. 2013 Dec;34(45):3515-24 |
| C57Bl/6J mice | Carfilzomib-induced nephrotoxicity model | Oral | 165 mg/kg | Daily administration for 6 days | To evaluate the protective effect of Eplerenone on Carfilzomib-induced nephrotoxicity, it was found that Eplerenone partially prevented the Carfilzomib-induced increase in creatinine and BUN, and restored urine volume, glomerular volume, and Lcn2 levels. | Hemasphere. 2022 Oct 18;6(11):e791. |
| Mice | Kcnmb1/H11002//H11002 mice | Oral | 100 mg/kg BW/day | Once daily for 10 days | To investigate the effect of Eplerenone on hypertension and fluid balance in Kcnmb1/H11002//H11002 mice. Results showed that Eplerenone corrected the fluid imbalance and significantly reduced hypertension. | Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11800-5 |
| 细胞系 | 浓度 | 检测类型 | 检测时间 | 活性说明 | 数据源 |
| 293 cells | Function assay | 16 h | Displacement of [3H]aldosterone from human mineralocorticoid receptor expressed in 293 cells after 16 hrs by scintillation counting, IC50=2.6 μM | 25187277 | |
| COS1 cells | Function assay | 1 days | Antagonist activity at human MR transfected in human COS1 cells after 1 day by luciferase reporter gene assay, IC50=1.3 μM | 22074142 | |
| Huh7 cells | Function assay | Antagonist activity at Gal4-tagged mineralocorticoid receptor expressed in human Huh7 cells by luciferase reporter gene assay, IC50=0.122 μM | 20672822 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.41mL 0.48mL 0.24mL |
12.06mL 2.41mL 1.21mL |
24.13mL 4.83mL 2.41mL |
|
| CAS号 | 107724-20-9 |
| 分子式 | C24H30O6 |
| 分子量 | 414.49 |
| SMILES Code | O=C([C@@H]1CC([C@]([C@]23[C@](C[C@@]([C@@]4(OCC(C4)=O)CC5)(C)[C@]5([H])[C@]13[H])([H])O2)(C)CC6)=CC6=O)OC |
| MDL No. | MFCD07783647 |
| 别名 | Epoxymexrenone; CGP 30083; Selara; Inspra; SC-6110; (+)-Eplerenone; SC-66110 |
| 运输 | 蓝冰 |
| InChI Key | JUKPWJGBANNWMW-VWBFHTRKSA-N |
| Pubchem ID | 443872 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 25 mg/mL(60.31 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1